Sign in

    Sam England

    CFA-qualified analyst at Berenberg

    Sam England is a CFA-qualified analyst at Berenberg, specializing in the coverage of European healthcare and medical technology companies, with a focus on firms like Medacta International. Known for his deep sector knowledge and rigorous approach, England provides insights and recommendations that have informed institutional investor decisions, helping to evaluate growth opportunities and sector performance. His career comprises substantial experience in healthcare equity research, and he currently operates from Berenberg’s London office. England holds the Chartered Financial Analyst (CFA) credential, underscoring his expertise in investment analysis and portfolio management.

    Sam England's questions to SMITH & NEPHEW (SNN) leadership

    Sam England's questions to SMITH & NEPHEW (SNN) leadership • H1 2025

    Question

    Sam England of Berenberg asked about the potential market share gains from the CatellaStem hip system, particularly in the ASC channel, and questioned the demand drivers for the CORI robotics system between hospital and ASC settings.

    Answer

    CEO Deepak Nath expressed satisfaction with the uptake of CatellaStem and its strong surgeon feedback across all settings. For the CORI robotics system, he highlighted that the focus is on both placements and utilization, with encouraging progress in ASCs and teaching institutions. CFO John Rogers added that CORI placements over-indexed in ASCs during Q2, reinforcing its strong fit for that channel due to its smaller footprint and lower capital cost.

    Ask Fintool Equity Research AI

    Sam England's questions to SMITH & NEPHEW (SNN) leadership • H1 2025

    Question

    Sam England of Berenberg asked about the potential market share gains from the CatellaStem hip system, particularly in the ASC channel, and inquired about the demand drivers for the CORI robotic system, specifically the split between hospital and ASC placements.

    Answer

    CEO Deepak Nath expressed satisfaction with the uptake of CatellaStem, noting strong surgeon feedback in the growing direct anterior approach segment. On robotics, he emphasized the focus is on both placements and utilization, with encouraging progress in ASCs. CFO John Rogers added that in Q2, CORI placements 'over-indexed' in ASCs, where its smaller footprint and lower capital cost are significant advantages.

    Ask Fintool Equity Research AI